Cargando…

Trends in steroid therapy for Duchenne muscular dystrophy in Japan

Introduction: We conducted a study to reveal trends in steroid prescription for Duchenne muscular dystrophy (DMD) patients in Japan. Methods: We asked patients (ages 5–20 years) identified in the patient registry and their clinicians about steroid therapy experiences. Regimen, dose, and starting age...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takeuchi, Fumi, Komaki, Hirofumi, Nakamura, Harumasa, Yonemoto, Naohiro, Kashiwabara, Kousuke, Kimura, En, Takeda, Shin'ichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5113709/ https://www.ncbi.nlm.nih.gov/pubmed/26910583 http://dx.doi.org/10.1002/mus.25083

Ejemplares similares

Prednisolone improves walking in Japanese Duchenne muscular dystrophy patients
por: Takeuchi, Fumi, et al.
Publicado: (2013)

Characteristics of Japanese Patients with Becker Muscular Dystrophy and Intermediate Muscular Dystrophy in a Japanese National Registry of Muscular Dystrophy (Remudy): Heterogeneity and Clinical Variation
por: Mori-Yoshimura, Madoka, et al.
Publicado: (2018)

Characteristics of Japanese Duchenne and Becker muscular dystrophy patients in a novel Japanese national registry of muscular dystrophy (Remudy)
por: Nakamura, Harumasa, et al.
Publicado: (2013)

Clinical trial network for the promotion of clinical research for rare diseases in Japan: muscular dystrophy clinical trial network
por: Shimizu, Reiko, et al.
Publicado: (2016)

Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: Current Status of Therapeutic Approaches
por: Shimizu-Motohashi, Yuko, et al.
Publicado: (2019)

A phase I study of TAS‐205 in patients with Duchenne muscular dystrophy
por: Takeshita, Eri, et al.
Publicado: (2018)

Cardiac conduction disturbances and aging in patients with Duchenne muscular dystrophy
por: Segawa, Kazuhiko, et al.
Publicado: (2017)

Exon-Skipping in Duchenne Muscular Dystrophy
por: Takeda, Shin’ichi, et al.
Publicado: (2021)

Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis
por: Shimizu-Motohashi, Yuko, et al.
Publicado: (2018)

Mammalian Models of Duchenne Muscular Dystrophy: Pathological Characteristics and Therapeutic Applications
por: Nakamura, Akinori, et al.
Publicado: (2011)

Early phase 2 trial of TAS‐205 in patients with Duchenne muscular dystrophy
por: Komaki, Hirofumi, et al.
Publicado: (2020)

Nationwide patient registry for GNE myopathy in Japan
por: Mori-Yoshimura, Madoka, et al.
Publicado: (2014)

Induction of Pluripotent Stem Cells from a Manifesting Carrier of Duchenne Muscular Dystrophy and Characterization of Their X-Inactivation Status
por: Miyagoe-Suzuki, Yuko, et al.
Publicado: (2017)

NS-065/NCNP-01: An Antisense Oligonucleotide for Potential Treatment of Exon 53 Skipping in Duchenne Muscular Dystrophy
por: Watanabe, Naoki, et al.
Publicado: (2018)

Left Ventricular End-Diastolic Diameter and Cardiac Mortality in Duchenne Muscular Dystrophy
por: Segawa, Kazuhiko, et al.
Publicado: (2020)

Viltolarsen in Japanese Duchenne muscular dystrophy patients: A phase 1/2 study
por: Komaki, Hirofumi, et al.
Publicado: (2020)

Comparison of Experimental Protocols of Physical Exercise for mdx Mice and Duchenne Muscular Dystrophy Patients
por: Hyzewicz, Janek, et al.
Publicado: (2015)

Current Challenges and Future Directions in Recombinant AAV-Mediated Gene Therapy of Duchenne Muscular Dystrophy
por: Okada, Takashi, et al.
Publicado: (2013)

Modelling Duchenne muscular dystrophy in MYOD1-converted urine-derived cells treated with 3-deazaneplanocin A hydrochloride
por: Takizawa, Hotake, et al.
Publicado: (2019)

Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors
por: Miyatake, Shouta, et al.
Publicado: (2016)

Dental pulp stem cells can improve muscle dysfunction in animal models of Duchenne muscular dystrophy
por: Nitahara-Kasahara, Yuko, et al.
Publicado: (2021)

Initial Pulmonary Respiration Causes Massive Diaphragm Damage and Hyper-CKemia in Duchenne Muscular Dystrophy Dog
por: Nakamura, Akinori, et al.
Publicado: (2013)

Publisher Correction: Modelling Duchenne muscular dystrophy in MYOD1-converted urine-derived cells treated with 3-deazaneplanocin A hydrochloride
por: Takizawa, Hotake, et al.
Publicado: (2020)

Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy
por: ANGELINI, CORRADO, et al.
Publicado: (2012)

Lung function monitoring in patients with duchenne muscular dystrophy on steroid therapy
por: Machado, Darlene L, et al.
Publicado: (2012)

Exon skipping induced by nonsense/frameshift mutations in DMD gene results in Becker muscular dystrophy
por: Okubo, Mariko, et al.
Publicado: (2020)

Mitochondria mediate cell membrane repair and contribute to Duchenne muscular dystrophy
por: Vila, Maria C, et al.
Publicado: (2017)

Survival in Duchenne muscular dystrophy
por: RALL, SUSANNE, et al.
Publicado: (2012)

Theragnosis for Duchenne Muscular Dystrophy
por: Luce, Leonela, et al.
Publicado: (2021)

Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases
por: Tsoumpra, Maria K., et al.
Publicado: (2019)

The PJ Nicholoff Steroid Protocol for Duchenne and Becker Muscular Dystrophy and Adrenal Suppression
por: Kinnett, Kathi, et al.
Publicado: (2017)

Efficacy of Prednisolone in Generated Myotubes Derived From Fibroblasts of Duchenne Muscular Dystrophy Patients
por: Kameyama, Tsubasa, et al.
Publicado: (2018)

Systemic administration of the antisense oligonucleotide NS‐089/NCNP‐02 for skipping of exon 44 in patients with Duchenne muscular dystrophy: Study protocol for a phase I/II clinical trial
por: Ishizuka, Takami, et al.
Publicado: (2023)

Hypokalemia complicating Duchenne muscular dystrophy.
por: McDonald, B., et al.
Publicado: (1987)

The role of fibrosis in Duchenne muscular dystrophy
por: KLINGLER, WERNER, et al.
Publicado: (2012)

Delay in Diagnosis of Duchenne Muscular Dystrophy
por: Rao, Vamshi K., et al.
Publicado: (2015)

Circulating Biomarkers for Duchenne Muscular Dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2015)

Targeting angiogenesis in Duchenne muscular dystrophy
por: Podkalicka, Paulina, et al.
Publicado: (2019)

Regenerative biomarkers for Duchenne muscular dystrophy
por: Guiraud, Simon, et al.
Publicado: (2019)

Eteplirsen in the treatment of Duchenne muscular dystrophy
por: Lim, Kenji Rowel Q, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_v1hsga8l2mpa1d455r4opkj84a